期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 7, 期 15, 页码 2155-2168出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.7.15.2155
关键词
cetrorelix; drug therapy; endometriosis; female infertility; gonadotropin; gonadotropin-releasing hormone; gonadotropin-releasing hormone agonist; gonadotropin-releasing hormone antagonist
The use of cetrorelix within ovarian-stimulation protocols demonstrates several advantages compared with gonadotropin-releasing hormone (GnRH) agonist-containing protocols, which include, for example, significantly less time for analogue treatment and a reduction in the amount of gonadotropins needed. Furthermore, fewer side effects can be expected. There is no difference regarding endometrium quality and hormone profiles, and the results of assisted reproduction cycles are comparable. Cetrorelix also seems to be useful in the treatment of endometriosis which, in most cases, is an estrogen-dependent disease. Furthermore, fewer side effects occur with this agent (e.g., postmenopausal symptoms) and no estradiol add-back is needed. In the future, new nonpeptic GnRH antagonists are expected to be available for oral administration. Although they are still under investigation, these agents have the potential to improve patients' comfort and compliance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据